Experimental diabetes drugs offer patients hope
Some experimental diabetes treatments in late testing offer patients hope of better controlling their blood sugar and weight and preventing dangerously low blood sugar, all big challenges for millions of diabetics.
Results from studies of several new diabetes medicines and insulin products, just announced at the premiere U.S. conference for diabetes specialists, likewise hold the promise of billions in annual revenue for drugmakers that have dominated the diabetes market and for others breaking into it. They have been presenting their data at the American Diabetes Association conference, held in Philadelphia from last Friday through Monday.
Until the last decade, relatively few companies made treatments for diabetes, a chronic condition in which the body either does not make enough insulin to break down the sugar in foods or uses insulin inefficiently.
That's because the global obesity epidemic has caused a similar explosion of diabetes cases. About 95 percent are Type 2 diabetes, usually related to being overweight and sedentary. Type 2, once called adult-onset diabetes, now is also being diagnosed in adolescents, just like insulin-dependent Type 1 diabetes, which used to be called juvenile diabetes.
Both types can cause early death or devastating complications blindness, amputations, stroke, kidney disease, heart disease and more when too-high blood sugar steadily damages organs and blood vessels.
Roughly $200 billion a year is spent on treating diabetes and indirect costs such as missed work and premature death, according to the diabetes association.
Last year, U.S. spending on diabetes medicines among insured patients for the first time exceeded spending on cholesterol drugs, according to Express Scripts, a top prescription benefit manager.
"We expect the key diabetes brands and markets to exhibit sustainable high-single-digit growth," reaching about $54 billion a year by 2020, Jefferies & Company analyst Jeffrey Holford recently wrote to investors. He cited an aging Western population, more health care use and adoption of Western diets in emerging countries, and increased use of new treatments and combination therapies.
Holford expects Denmark's Novo Nordisk AS to remain the top diabetes company by revenue but Eli Lilly and Co. of Indianapolis to overtake France's Sanofi SA as the No. 2 player by 2017.
Among other research, the conference highlighted promising new treatments likely to be approved in the next few years:
Novo Nordisk on Friday reported on results of degludec, its ultra-long-acting insulin for patients with Type 2 diabetes. Its yearlong, 1,030-patient study compared degludec with Sanofi's Lantus, the world's top-selling insulin. Degludec reduced low blood sugar during the night, when it's most dangerous, by 36 percent and also reduced severe hypoglycemia significantly, compared to Lantus. Those problems occurred less than once in a year in both groups of patients, though.
Novo also reported on other studies finding that because degludec is active in the body for more than the standard 24 hours for long-acting insulins, patients can maintain good blood sugar control even if they don't take it at the same time every day. The Food and Drug Administration was to decide whether to approve U.S. sales by June 29, but just pushed that back until Oct. 29 to allow more time to review data.
Johnson & Johnson's Janssen Research unit presented five late-stage studies on its daily Type 2 diabetes pill, canagliflozin, part of a newer class of diabetes drugs called SGLT2 inhibitors. They work primarily by increasing how much glucose is excreted in urine. One yearlong study found it reduced long-term blood sugar levels, called A1C levels, and also helped patients lose much more weight than Merck & Co.'s blockbuster pill Januvia. Januvia is in a class called DPP-4 inhibitors, which increase the body's release of insulin after a meal.
Another study similarly showed canagliflozin decreased A1C levels and body weight significantly more than Sanofi's diabetes pill Amaryl. J&J applied for U.S. approval of its drug on May 29.
On Sunday afternoon, Eli Lilly and partner Boehringer Ingelheim of Germany released results from two mid-stage studies of their new short-acting insulin, known as LY2605541. In separate studies comparing it to Lantus, it was slightly better at reducing blood sugar levels in Type 1 diabetics and about the same in Type 2 diabetics. In the eight-week Type 1 study, patients getting LY2605541 lost about 2.5 pounds (1.13 kilograms) on average while those on Lantus gained 1.5 pounds (0.68 kilograms). Weight changes were similar, but smaller, in the Type 2 study.
LY2605541 still must go through late-stage testing before approval can be sought.
Other companies were presenting data on an experimental patch to deliver insulin pain-free and two devices in early development that would work like an artificial pancreas, monitoring blood sugar continuously to help control when an insulin pump releases the hormone into the patient's blood.
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Novo Nordisk says to market improved insulin in 2013 Dec 23, 2010 | not rated yet | 0
- FDA approves new diabetes treatment Oct 17, 2006 | not rated yet | 0
- Which diabetes drug is best for diabetics with kidney disease? Nov 13, 2011 | not rated yet | 0
- Combining exenatide with insulin may be 'best result ever' for diabetes patients: UNC expert Dec 06, 2010 | not rated yet | 0
- FDA approves first diabetes-cholesterol combo pill Oct 07, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Indeterminism in Classical Physics
2 hours ago I was reading the Roger Penrose book Emperor's New Mind and he was explaining the determinism in Newtonian mechanics. He says that if we consider...
Current in two wires
2 hours ago Wire A and B, which have the same cross-sectional area are connected in series. There is a p.d. V across the whole wire. Suppose the two wires...
understanding the dipole model for Rayleigh scattering
4 hours ago Hello. I am currently studying scattering theory in detail for my BSc thesis, and I'm starting with Rayleigh scattering. I'm following Scattering...
question on coriolis effect with drag force
10 hours ago I really need help with this question. A small floating object initially moves with velocity v on the surface of a liquid at latitude λ. The...
Question of reflection and transmission of TEM wave in normal incidenc
16 hours ago Suppose TEM wave in +z normal to a boundary on xy plane at z=0. We know *E* & *H* are tangential to the boundary. Let ##\vec E_i=\hat x E##, be the...
the rudyak-krasnolutski effective potencial
17 hours ago Hi ... anyone now how to calculate or the formula of the rudyak-krasnolutski EFFECTIVE potencial ? the effective potencial includes the angular...
- More from Physics Forums - Classical Physics
More news stories
(HealthDay)—Type 2 diabetes is more aggressive in children than adults, with signs of serious complications seen just a few years after diagnosis, new research finds.
Diabetes 12 hours ago | not rated yet | 0
Treatment with high potency statins (especially atorvastatin and simvastatin) may increase the risk of developing diabetes, suggests a paper published today in BMJ.
Diabetes 14 hours ago | not rated yet | 0
Ethnic background plays a surprisingly large role in how diabetes develops on a cellular level, according to two new studies led by researchers at the Stanford University School of Medicine.
Diabetes 16 hours ago | not rated yet | 0 |
Widely-used fish oil supplements modestly increase amounts of a hormone that is associated with lower risk of diabetes and heart disease, according to a study accepted for publication in The Endocrine Society's Journal of ...
Diabetes May 22, 2013 | 5 / 5 (2) | 1
Study shows that women who smoke during pregnancy increase the risk of both obesity and gestational diabetes in their da
Women who smoke during pregnancy increase the risk of both obesity and gestational diabetes, in their daughters, concludes research published in Diabetologia, the journal of the European Association for the Study of Diabet ...
Diabetes May 20, 2013 | not rated yet | 0
(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.
59 minutes ago | not rated yet | 0
(Medical Xpress)—Patients with diabetes who are depressed are much more likely to develop episodes of dangerously low blood sugars, or hypoglycemia, than are those who are not depressed, a new study has ...
55 minutes ago | not rated yet | 0 |
(Medical Xpress)—UCD researchers led by Conway Fellow, Professor David Brayden in UCD School of Veterinary Medicine have successfully reduced inflammation in the swollen arthritic knees of a murine model using a novel nanoparticle.
9 minutes ago | not rated yet | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
29 minutes ago | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
19 minutes ago | not rated yet | 0
A new program for treating the emotional health of mothers of children with ADHD has shown significant benefits for the children themselves, finds a new study by University of Maryland researchers. The program combines treatment ...
29 minutes ago | not rated yet | 0